Ribosomal DNA is one of the most variable regions in the human genome with respect to copy number. Despite the importance of rDNA for cellular function, we know virtually nothing about what governs its copy number, stability, and sequence in the mammalian genome due to challenges associated with mapping and analysis. We applied computational and droplet digital PCR approaches to measure rDNA copy number in normal and cancer states in human and mouse genomes. We find that copy number and sequence can change in cancer genomes. Counterintuitively, human cancer genomes show a loss of copies, accompanied by global copy number co-variation. The sequence can also be more variable in the cancer genome. Cancer genomes with lower copies have mutational evidence of mTOR hyperactivity. The PTEN phosphatase is a tumor suppressor that is critical for genome stability and a negative regulator of the mTOR kinase pathway. Surprisingly, but consistent with the human cancer genomes, hematopoietic cancer stem cells from a Pten-/- mouse model for leukemia have lower rDNA copy number than normal tissue, despite increased proliferation, rRNA production, and protein synthesis. Loss of copies occurs early and is associated with hypersensitivity to DNA damage. Therefore, copy loss is a recurrent feature in cancers associated with mTOR activation. Ribosomal DNA copy number may be a simple and useful indicator of whether a cancer will be sensitive to DNA damaging treatments.
Repetitive regions in the human genome include ribosomal DNA (rDNA), telomeres, and centromeres, and these regions have profoundly important functions for genome stability [1,2, 3]. While challenging to study, genetic variability of these regions is ripe for selection. The rDNA encodes the functional RNAs of the ribosome, the most conserved and utilized genes in the genome. Three of the four RNAs are transcribed initially as a single transcript by RNA polymerase I. The repeats encoding the RNAs are present on five different regions on human acrocentric chromosomes, with each region composed of several copies of the gene, referred to as 45S. 45S is processed into three separate RNAs (28S, 5. 8S, and 18S). The fourth RNA is encoded by the 5S genes, located on human chromosome 1 and transcribed by RNA polymerase III. The number of 5S copies correlates with 45S [4]. The loci that encode the rRNAs are transcribed at incredibly high rates, with rRNA often constituting as much as 80% of the RNA in actively proliferating cells, to meet the demand for ribosome production. Even so, only about 50% of the repeats are transcribed. The number of repeats is variable in human genomes [5], with one recent computational study estimating between 14–410 copies of 45S [4]. The variability in number combined with five different chromosomal locations makes the 45S pattern unique in each human genome. The human 45S genes are highly recombinogenic, with an estimated 10% recombination in a single generation [6]. The sequence of the 45S repeat within a species is highly conserved due presumably to high rates of recombination which allow for concerted evolution [7]. While repeats exist mainly in a head to tail tandem arrangement, palindromic arrangements have also been observed, especially in syndromes with increased genomic instability [8]. One can imagine that one way for a cell to achieve high rates of protein synthesis would be to expand the number of rDNA copies, especially given that ribosomal RNA can be limiting for ribosome biogenesis [9]. In fact, increases in copy number occur in different developmental and disease contexts. Expansions occur in frog oocytes [10] and the macronucleus of tetrahymena [11] as part of the normal course of development, presumably to help achieve high rates of ribosome biogenesis and protein synthesis. Southern blotting experiments demonstrate that recombination at the rDNA is common in adult lung and colorectal cancer [12], suggesting the possibility that the rDNA may be affected in the cancer genome. However, copy number of the rDNA in mammalian development and disease has not been examined. The TOR (target of rapamycin) kinase detects the nutritional environment and promotes ribosome biogenesis when amino acids are plentiful. The PTEN (phosphate and tensin homolog) phosphatase is a negative regulator of mTOR activity and acts as a tumor suppressor. Somewhat paradoxically, overfeeding flies, which overstimulates mTOR, has been associated with contraction of the rDNA copy number in the germline in Drosophila, transmitted transgenerationally [13]. TOR signaling was required for the amplification from low copy number back to normal copy number in budding yeast [14]. Together these results suggest there may be a connection between TOR signaling and the rDNA copy number, but this has not been explored in the mammalian genome. Furthermore, if the copy number or sequence changes in response to the environment, then rDNA may act as both a sensor and adaptor under stress conditions. In addition to its role in ribosome biogenesis, the rDNA has many extra-ribosome functions, such as regulating gene expression, chromosome organization, and titrating chromatin factors [15,16,17,18]. The nucleolus, which contains the ribosomal DNA, is a hub for many signaling pathways and can act as a stress sensor. Chromosomal domains from most human chromosomes are associated with the nucleolus [19,20], highlighting its role as an organizer. Dramatically reducing the copy number in yeast does not cause reduction in rRNA levels, but causes all repeats to become active (sometimes termed “compensation”) and the yeast are hypersensitive to DNA damage [21]. In contrast, low copy compromises protein synthesis and development in the bobbed mutants in Drosophila [22]. Furthermore, copy number of the rDNA titrates position effect variegation in flies [15,18,23]. Therefore, modulation of copy number has the potential to regulate signaling, genome stability, chromosome organization, and gene expression without necessarily affecting ribosome biogenesis. Recent technological developments enable accurate and high throughput measurements of the copy number of the rDNA. Copy number can be estimated from whole-genome sequence (WGS) and droplet digital PCR (ddPCR). The plethora of cancer genome sequencing projects allows comparison between the copy number in the tumor genome versus the normal genome from a single individual. We used these new technologies to analyze how rDNA copy number changes in different tissues and in cancer. Surprisingly, rDNA copy number is reduced in cancer genomes with mTOR activation, providing evidence that copy number can be altered in a natural system. We also discovered co-occurring increased copy number of additional genes, and evidence for single nucleotide variation in the repeats. Using cancer stem cells derived from a mouse model for leukemia driven by loss of Pten, we find that copy loss does not compromise proliferation, rRNA production, or protein synthesis, but cells are hypersensitive to DNA damage. These data suggest that the ribosomal DNA can act as a sensor and adaptor to cancer-associated stress. Copy number may be a biomarker with predictive potential.
In the mouse genome, the 45S repeats are located on 5 different chromosomes (12,15,16,18,19) whereas all the 5S repeats are located on chromosome 8. The copy number for the two repeats co-varies and has been previously estimated using a computational approach from sequence data derived from a collection of laboratory and wild mice, showing a 10-fold range with values for 45S of 31–289 and for 5S of 32–224 [4]. We wanted to extend these findings by developing a ddPCR method to directly measure the copy number of the 45S repeat with high accuracy in commonly used laboratory strains including the inbred strains C57BL/6 and DBA/2J, and the outbred strain CD-1. In addition, we wanted to know whether copy number varied by tissue given different metabolic requirements. Mitochondrial DNA (mtDNA) copy number has been reported to have an inverse relationship with rDNA copy number in human blood samples [17] and is thought to fluctuate with metabolic demand. To answer whether rDNA copy number is variable across different mouse strains, tissues, and organs, we collected genomic DNA (gDNA) from fifteen tissues of three mouse strains, and performed ddPCR. The assay is designed such that the copy number of 45S and the single copy gene Gapdh1 are measured in the same reaction using fluorescent probes. We found the average copy number for C57BL/6 was 156 based on 57 tissue measurements from eight mice (standard deviation is 13. 1), and DBA/2J was 123 based on two mice (standard deviation is 12. 3) (Fig 1, S1 Fig). The mouse to mouse variation in the inbred strains was ~10%, with no obvious gender difference (S1 Fig). While the mean copy number for CD-1 was similar (145 based on 5 mice), the variation between individuals was much higher (standard deviation is 43. 2), as much as 2-fold in the individuals tested. This demonstrates that mice from inbred strains tend to have a much more similar copy number to each other than individuals from the outbred CD-1 strain. The copy number variation in CD-1 is more like what has been reported in the human population. Next we addressed how copy number varies across tissues and organs. To first address the level of variation in the ddPCR protocol, we isolated gDNA from the same tissue after dividing it into three samples. In this case the variability is usually less than 5% (S2 Fig). The results suggest that the accuracy of the measurements is appropriate to assess levels of variation higher than 5%. rDNA copy number differs by up to 15% between tissues from the same individual, and this is true in all three strains (Fig 1, S1 Fig). This variation is similar to individual to individual differences from the two inbred strains. From these studies, we conclude that the changes reported in mtDNA copy number in various tissues are not mirrored by equivalent changes in rDNA copy number, since the tissue to tissue variation in a single individual for rDNA is low but for mtDNA is high. Given the result that tissues from the same individual have very similar rDNA copy numbers, this opens the possibility of using matched cancer-normal genome data to explore rDNA copy number using previously developed computational methods that use genome coverage for normalization [17]. We analyzed high-coverage tumor-normal matched WGS data from 162 individuals across eight tumor types, including 19 childhood acute lymphoblastic leukemia samples (ALL, phs000341) [24], 36 medulloblastoma samples (phs000409) [25], 16 core-binding factor acute myeloid leukemia samples (CBF-AML, phs000414), 40 prostatic neoplasm samples (phs000447) [26], 12 AIDS-related lymphoma samples (phs000530), 12 intestinal neoplasm samples (Liver/Small bowel, phs000579) [27], 13 osteosarcoma samples (phs000699) [28], and 14 esophageal adenocarcinoma samples (phs000598) [29]. The normal WGS data was derived from either blood, solid normal tissue, or germline tissue (S1 Table). We also analyzed the rDNA copy number in WGS data derived from blood of 143 normal individuals (phs000424, GTEx). These datasets were chosen for three reasons: 1) we wanted representation of both solid and blood tumors, 2) WGS data was available and 3) permission to use the data for this analysis was granted. The use of ~16,000 exons for normalization and the comparison of many tumor-normal pairs helps to offset concerns regarding how aneuploidy in the cancer genomes might skew results (see Materials and methods). To first verify the bioinformatics method, we compared our copy number measurements between the three different regions of the 45S gene for all the normal samples. We found good pairwise correlations between 18S, 5. 8S, and 28S genes (Fig 2A), similar to those previously reported with this method [17]. We next calculated the copy number for the normal and tumor matched samples. The copy number of 18S, 5. 8S, and 28S for the normal samples was subtracted from the tumor for each individual and plotted as the normalized copy number. We found three cancer genome projects, osteosarcoma, AIDS-related lymphoma, and esophageal adenocarcinoma, for which there was a statistically significant reduction in copy number (~70–90 copies) for the tumor genomes (Fig 2B–2D). The other five genome projects did not show significant changes (S3 Fig), suggesting the method can discern loss vs. no loss. We found this result remarkable because it suggests that over the course of tumor development a lower copy number at the rDNA is selected in some cancers. This is opposite to the idea that more copies might be needed in cancer to reach high rates of ribosome biogenesis required for high rates of protein synthesis and proliferation. Instead, some other aspect of high proliferation may select for a lower copy number, for instance, efficient DNA replication. These findings represent the first demonstration that rDNA copies can be lost as part of cancer development. We used the ~16,000 exons selected for normalization, which are scattered across all chromosomes, to examine whether the chromosomes with rDNA (13,14,15,21,22) are present at lower levels relative to other chromosomes in the tumor genomes, since this would indicate chromosome loss as one mechanism to lose rDNA copies. These exons were preselected based on the criteria that they were derived from the largest exon (300 bps or larger) of a single gene, mapped uniquely in the genome, and did not have sequence similarity to each other. Using sequencing coverage, we found evidence that chromosomes in the tumor genomes show more variable coverage than in the normal genomes (S4A Fig), presumably reflecting increased aneuploidy. However, the chromosomes with rDNA are not lost at higher rates in genome projects that are positive for rDNA loss compared to the genome projects negative for rDNA loss (S4B Fig). These results suggest preferential loss of rDNA chromosomes is not the predominant mechanism underlying loss of rDNA copies in the cancer genome projects showing a net loss of rDNA copies. To further analyze copy number variation in the cancer genome projects, we used the copy number of the preselected exons used for normalization to discover additional genes whose copy number co-varied with the ribosomal DNA. Exons were selected that displayed a significant copy number difference based on results of a paired t test for all the tumor versus all the normal values for each exon for each genome project (FDR< = 0. 05). For the three genome projects with low rDNA copy number in tumor versus normal (phs000530, phs000598, phs000699) there were 353 such exons. We then used hierarchical clustering to identify exons with similar trends in copy number (gain or loss) in the three “positive” projects compared to the five “negative” projects. The “gain” cluster was the most striking, with ~100 exons (Fig 3A). These exons are spread across all chromosomes and are not confined to the chromosomes with 45S genes, indicating global rather than local structural variations accompany the loss of copies. This result suggests there may be a global concerted genomic signature associated with decreased rDNA copies in cancer. The GO terms associated with the genes from which these exons were derived include DNA damage response and metabolic regulation, among others (Fig 3B, S2–S4 Tables), suggesting the increase in copy number of these genes could affect cellular physiology. While none of these terms reach statistical significance when adjusted for multiple hypothesis testing, there are conflicting views on whether this adjustment is necessary for GO term analysis. Unfortunately, RNA-seq data was not available for these cancer genome projects, which would have allowed us to evaluate if there was a corresponding gene expression signature. The rDNA represents a prime example of concerted evolution, which refers to the fact that within a species there is very little sequence variation, but there is significant variation between species [7]. The homogeneity is thought to be maintained via frequent and continuous sweeps of recombination. However, variation in the ribosomal DNA sequence has not been assessed in the human genome. We identified single nucleotide variants (SNVs) and indels in tumor and normal genomes relative to a common reference. Indels were rare so we focused on SNVs. Within a single individual, the majority of SNVs (~90%) detected relative to the reference were shared between the tumor and normal genome. However, subtraction of the shared SNVs still yielded several unique SNVs. The number of unique SNVs were similar in tumor and normal genomes across the 8 different projects (Fig 4A, S5 Table). When taken in aggregate, the number of SNVs in the cancer genomes is not higher than in the normal genomes. These results suggest that as cells divide, SNVs can arise at the rDNA and propagate at a similar level in tumor and normal cells. One might predict the coding portion of the locus to experience selective pressure to generate functional ribosomes for high proliferation. SNVs were binned for each region of the repeat (Fig 4B). Previous work in yeast has suggested the most variable region is the non-transcribed portion, because mutations here might have the least functional consequences [30]. The human repeat is ~30% transcribed (ETS, ITS, 18S, 5. 8S, 28S) and ~70% non-transcribed (IGS). We found that the regions encoding 18S and 5. 8S had virtually no SNVs in either the tumor or normal genomes, suggesting these sequences cannot tolerate mutations, consistent with a previous report in yeasts [30]. Surprisingly, SNVs were detected in the 28S region, with a similar number in tumor and normal genomes. We detected hotspots for variation; the 189 SNVs were located at only 22 unique positions (Fig 4C). SNVs in the gene encoding 28S rRNA have the potential to affect ribosome function if the corresponding repeats are transcribed. All non-coding regions of the human repeat had SNVs, including the 5’ and 3’ external transcribed spacer regions, the internal transcribed spacers, as well as the large intergenic region, suggesting these regions can tolerate SNVs. Interestingly, the IGS did not appear to be mutated at a significantly higher rate than the overall repeat (Fig 4B, S6 Table). SNVs in the transcribed non-coding regions have the potential to affect transcription and processing of rRNA but are difficult to functionally evaluate given our limited understanding of the sequence features of the human repeat. In summary, variation in the non-coding region is higher than in the coding region, regardless of transcription. Moreover, the amount of variation is generally similar in the normal and tumor genomes. Another way to quantify variation that pertains specifically to a multi-copy sequence in the genome is allele number. By this we mean that individual nucleotide positions could have sequence evidence for more than one base, which we refer to as alleles. For the shared SNVs, we evaluated the number of alleles present in the cancer and normal genomes, to ask whether there was differential presence of alleles. We found three genome projects with evidence for more minor alleles in the tumor as compared to normal genomes (Fig 4D). The modest increase observed in prostate neoplasms (phs000447) could be due to the handful of cancer genomes in this project with very high copy number. Most notably, the esophageal adenocarcinoma (EAC) genomes have an increased allele frequency relative to the matched normal genomes (phs000598), despite having a lower copy number. Therefore, in the EAC genomes, there are more alleles of the 45S gene sequence despite fewer copies. The initial publication describing the analysis of the EAC genomes reported mutational complexity with accumulated mutations including activating mutations in PIK3CA, and loss of function mutations in PTEN, PIK3R1, AKT2, and AKT3, together implicating the mTOR-PTEN pathway in some instances of this cancer [29]. Our results reveal that the mutational complexity of this cancer also encompasses variation in 45S. Overall, our sequence analysis of the human 45S repeats indicates a surprising level of SNVs with newly identified hotspots in the human 28S gene, and some cancer genomes with evidence for increased alleles. In the osteosarcoma genome project the tumors are driven by increased mTOR pathway activity, which can occur via multiple different mutations, including loss of PTEN, a negative regulator of mTOR [28]. Loss of PTEN in prostate cancer is associated with tumor aggression and poor outcome. In fact, mutations that activate the PI3K (phosphatidylinositol-3-kinase) -mTOR pathway are frequently found in many cancers, including AIDS-related lymphomas [31], and esophageal cancer, as mentioned above [29,32,33,34]. PTEN is widely known as a tumor suppressor and a guardian of the genome [35]. Because the samples used for the cancer genome projects have a mixed population of mutations, may have genetic instability, and may be derived from mixtures of cell types, we wanted to specifically address whether high mTOR function could influence rDNA copy number in the context of a uniform genetic alteration (loss of Pten) in a pure cell population. We used a mouse model for Pten-/- leukemia in the C57Bl6 background to assess rDNA copies in hematopoietic stem cells (HSCs) [36]. Pten is excised in bone marrow HSCs postnatally, but remains intact in all tissues other than the progeny of null HSCs. HSCs were isolated from mice using flow sorting of Lineage-, Sca-1+, c-Kit+, and CD34- cells from bone marrow prior to progression to leukemia; these cells are cancer stem cells which will eventually develop to myeloid proliferative disorder and leukemia in vivo or upon transplant [37]. These cells are not aneuploid, based on analysis of a model with similar progression to leukemia [38]. Pten null cells isolated from bone marrow show more colony forming units and reduced quiescence, demonstrating increased proliferation [36,37]. We verified that loss of Pten in HSCs results in a pathway signature indicative of mTOR activation, including higher levels of phosphorylated mTOR, Rps6, and S6K1 (S5 Fig). Remarkably, the Pten-/- HSCs have significantly lower copy number compared to two different controls, tail samples from the same mice which retain Pten and matched Pten+/+ HSCs (Fig 5A and 5B). To examine rDNA copy number, we collected WT and Pten-/- HSCs from 20 single-cell derived clones from two different mice per genotype (see Materials and methods), and extracted gDNA from these samples for the ddPCR assay. Each Pten-/- clone had lost about 40 copies, approximately 20% of their total. HSC clones derived from three additional WT-null pairs showed similar results (S5 Fig), for a total of 5 pairs of female mice. Therefore, loss of Pten in HSCs was associated with significant loss of rDNA copies while the copy number in the tails was comparable. We constructed and sequenced libraries from genomic DNA derived from 20 WT and 20 Pten-/- clones derived from two age and sex matched females. Using our computational method, counting of the 5. 8S and 18S sequences showed a loss of ~30 copies in the Pten-/- clones, and 28S showed a loss of ~20 copies (S6 Fig). Given that the libraries were made using a transposase method that has some bias, the agreement between the computational and ddPCR methods is quite good, and lends confidence in the overall trend toward loss in Pten-/- HSCs. This trend is consistent with the lower rDNA copies observed in the genomes of osteosarcoma, AIDS-related lymphoma, and esophageal adenocarcinoma. WT and Pten-/- clones have similar ploidy (S6 Fig), indicating that chromosome loss is not the mechanism by which rDNA is lost in this context. Further analysis of the DNA sequences from the 40 clones revealed 110 SNVs relative to the consensus sequence that were shared between WT and Pten-/- clones. There were a handful of SNVs that occurred uniquely in Pten-/- (9) or WT clones (28), with most occurring in the large IGS region (5 for WT and 17 for Pten-/-). No SNVs were detected in 18S or 5. 8S, but 3 were detected in 28S. Overall the SNV pattern is similar to that observed in the human genome. Together these results suggest that in some cancers, and specifically in loss of PTEN, loss of rDNA copies may provide some selective advantage for the cancer genome. Furthermore, in the Pten-/- HSC model, loss of copies is a relatively early event, prior to progression to leukemia or aneuploidy. PTEN plays a critical role in the maintenance of chromosome stability, preventing double-strand breaks (DSBs) [39]. Deletion of PTEN in prostate cancer cells is associated with sensitivity to DNA damaging agents including ionizing radiation, mitomycin-C, UV, H2O2, and methyl methanesulfonate (MMS) [40]. Loss of PTEN in HCT116 colon cancer cell lines confers sensitivity to ionizing radiation [41]. We found that the Pten-/- HSCs were more sensitive than WT HSCs to DNA damage, including bleomycin and ionizing radiation (Fig 5C and 5D, S5 Fig), and MMS and hydroxyurea at the higher concentrations tested (Fig 5E and 5F, S5 Fig), consistent with Pten protecting against DNA damage in HSCs. HSCs were stained with antibodies to the nucleolar proteins fibrillarin and nucleolin, and nucleoli were imaged. Despite loss of copies, nucleolar size is not significantly different between Pten-/- and Pten+/+ HSCs (S7 and S8 Figs). To further examine how loss of copies affects cell function, we compared Pten-/- and control HSCs in culture. Pten-/- single cell derived colonies have more cells than controls (Fig 6A), consistent with previous reports that Pten-/- HSCs proliferate faster. Furthermore, we examined the production of rRNA using 3H-uridine incorporation. Because rRNA is the most abundant RNA product, this method has been widely used as a proxy to measure rRNA synthesis. We found that rRNA production is more robust in the Pten-/- HSCs compared to Pten+/+ HSCs despite reduced rDNA copy number (Fig 6B). This result is consistent with previous reports that PTEN normally represses both RNA polymerase I- and RNA polymerase III-dependent transcription [42,43]. Moreover, global protein synthesis, as measured by 35S-methionine incorporation, was significantly higher in the Pten-/- HSCs (Fig 6C), consistent with a previous study [44]. Therefore, loss of copies and DNA damage sensitivity occurs in the context of more robust proliferation, rRNA production, and protein synthesis. To determine whether the DNA damage sensitivity was due to fewer copies or the activation of mTOR, we treated HSCs with INK128 to block TOR activity and asked whether the Pten-/- HSCs were still sensitive to DNA damage. For these experiments HSCs were derived from 3 age matched pairs of male mice. First we identified a concentration of INK128 that would effectively block TOR activity in the HSCs (Fig 7A). Second, we measured copy number by ddPCR, finding loss of ~30 copies in Pten-/- HSCs that occurred independent of treatment with INK128 (Fig 7B). The copy number in the tails of mice was similar across animals and similar to the copy number in the WT HSCs (Fig 7C). Next we measured rRNA production (Fig 7D) and protein synthesis (Fig 7E). These outputs depended on mTOR activity, as expected, and were effectively normalized between the genotypes in the presence of INK128. Together with the results in Fig 6, these results demonstrate similar behavior between HSCs derived from male and female mice, with 8 pairs examined in total. Finally, we examined the sensitivity of the mTOR-blocked HSCs to bleomycin. Importantly, the Pten-/- HSCs are more sensitive to bleomycin than the WT HSCs (Fig 7F), suggesting that the sensitivity is not due to differential activation of mTOR, but could derive from the lower copy number. Finally, we asked whether copy number can change rapidly in human retinal pigment epithelial (RPE) cells grown in culture. RPE cells have a normal karyotype such that the droplet digital PCR method, which uses a single copy reference gene to calculate copy number, can be applied. RPE cells were transfected with 3 different siRNAs to knockdown PTEN, or a control siRNA. The knockdown of PTEN was confirmed by Western blot (S9 Fig). The copy number of the RPE cells was determined at 80 hours post-transfection, or after about 3 doublings. Under these conditions the copy number is not altered (S9 Fig). This result suggests that loss may require more doublings, or may require other environmental factors provided in an animal, such as cell-cell competition. This finding suggests that the loss of copies is not an immediate event upon loss of PTEN and is consistent with the result in the HSCs that short term treatment with an mTOR inhibitor is not sufficient to alter the copy number. Our findings suggest that in hematopoietic cancer stem cells, cell growth and ribosome biogenesis can occur robustly with ~30–40 fewer rDNA repeats. Interestingly, in budding yeast, loss of rDNA copies is associated with sensitivity to DNA damage [21]. Our results show that mouse HSCs without Pten function have fewer copies and are similarly sensitive to DNA damage. With only half of the rDNA repeats normally transcribed, loss of repeats can be compensated by increasing the fraction transcribed in yeast. However, the binding of factors that normally associate with the inactive repeats to maintain the stability of the locus may be compromised, increasing the sensitivity of yeast with fewer repeats to DNA damage [45]. It remains to be determined whether compensation occurs in the mammalian genome, and whether the absence of silenced repeats could cause DNA damage sensitivity. Nevertheless, copy number may be a useful predictor of DNA damage sensitivity.
We have used both computational approaches and ddPCR to analyze the copy number and sequence of the rDNA in mammalian cells. We find tissue to tissue variation in copy number in a single mouse is relatively low, as is individual to individual variation within an inbred strain. However, in an outbred mouse strain, the level of variation is higher, more resembling the situation in human genomes. We report for the first time that some cancer genomes, and in particular genomes associated with high mTOR activity, tend to have fewer copies than the matched normal genomes, a finding replicated in mouse cancer stem cells, and consistent with a previous report demonstrating transgenerational loss of rDNA copies in D. melanogaster with overactive TOR [13]. The low copy cancer genomes show concerted copy number changes in additional genes, suggesting a structural signature for these genomes. rDNA sequence variation can also occur in cancer genomes. Low copy in the Pten-/- HSCs is associated with sensitivity to DNA damage, extending previous reports that PTEN guards against genome instability. Our results suggest that copy number and sequence can change in the mammalian genome in cancer, and that loss of copies may have both costs and benefits. Future studies further analyzing the mechanisms and functional consequences of genomic alterations at the rDNA in mammals are warranted. Given our findings, it seems possible that ribosomal DNA could exhibit changes in other contexts. Loss of rDNA repeats may affect genome function and chromosomal processes via the release of protein factors. The rDNA locus houses many pluripotency factors in mammalian cells, including Oct4 [46]. The rDNA also contains binding sites for Myc [47], a key transcription factor for proliferation that can also affect DNA replication [48], and CTCF [49], a key chromosome organization protein. The rDNA chromatin contains many different histone modifications [49], which could sequester chromatin readers and writers. Finally, nucleolar associated domains are enriched in regions displaying heterochromatin signatures in Arabidopsis [50] and rDNA copy number titrates position effect variegation, a heterochromatin based silencing phenomenon in Drosophila [23]. Losing repeats has the potential to liberate factors for re-distribution to the rest of the genome which could affect chromosome organization, gene expression, and replication. Interestingly, PTEN has been shown to directly control the function of the DNA replication factor MCM2 during DNA replication stress [51]. Replication stress occurs at the rDNA and has been reported as a potent driver of functional decline in HSCs [52]. In a mouse model for cancer driven by deficiency in Mcm2, genomic deletions can occur [53]. Spontaneous DSBs also occur at higher levels upon loss of PTEN [39]. Together these findings suggest that one possible reason that rDNA repeats are lost in the absence of PTEN is that DSBs and replication stress are handled without MCM2 function, and repair events are required. The repair events that result in deletions may be selected for, since the rDNA is difficult to replicate and loss of repeats might facilitate a successful cell cycle. We suggest that rDNA may both sense and adapt to genomic stress, with PTEN-mTOR normally guarding against copy loss. Extrachromosomal expansions of rDNA have been reported in frog oocytes [10]. This expansion is thought to facilitate the production of rRNA for ribosome biogenesis and the translational requirements in these cells. Based on this finding we predicted that cancer cells might expand the repeats due to similar requirements. Instead, we found recurrent evidence for contractions. We note that there is a key difference between the oocyte and the cancer cell—rounds of DNA replication. We speculate that the requirement to replicate the rDNA in cancer may select for the loss of repeats while the lack of replication in the oocyte may allow the expansion to be tolerated. The timing of the loss of the repeats relative to the development of cancer cannot be determined from the cancer genome projects. However, in the mouse HSCs loss occurs prior to the development of leukemia and aneuploidy, at the stage of a cancer stem cell. Further characterization of the selective forces and timing of loss will be interesting questions for the future. Linking the rDNA to both genome stability and ribosome biogenesis may enable it to act as a critical molecular sensor. Changes in translation are associated with cancer [54]. Myc and PI3K-AKT-mTOR are major oncogenic signaling pathways that promote reprogramming of translation. Studies to date have focused on mRNA regulatory elements, tRNA function and codon usage bias, and adaptations to stress that affect translation, but not ribosomal DNA copy number as a factor under the control of TOR signaling. Protein synthesis is quite tightly regulated in HSCs and defects that arise via loss of Pten or silencing of rDNA repeats cause functional decline and aging [44,52]. Our study suggests that rDNA copy number and sequence can be altered in human cancers. HSCs with fewer copies are more sensitive to DNA damage, but are not compromised for rRNA production, proliferation, or protein synthesis. We speculate that the extra inactive copies may normally serve in part to counteract rDNA instability. Together, our data and others show that multiple mechanisms regulate protein synthesis and genome stability to control aging and prevent leukemogenesis in HSCs, and that these processes may be linked using the rDNA as a sensor. In summary, the rDNA copy number and sequence can change in cancer, with high mTOR activity associated with contractions and DNA damage sensitivity. With this recognition comes the possibility to target these loci. Cancer stem cells with low copy number may be more sensitive to DNA damaging agents. We speculate that this single copy number measurement could be used as a proxy detector for the variety of mutations that can occur in the PI3K-AKT-mTOR pathway in cancer and a predictor of whether DNA damaging drugs would selectively target the cancer stem cells. These findings may be applicable to cancer diagnosis and therapeutic choice.
All animals were handled in strict accordance with good animal practice as defined by the relevant national and/or local animal welfare bodies, and all animal work was approved by the Stowers Institute for Medical Research, Institutional Animal Care and Use Committee. Animals were sacrificed by carbon dioxide administration. All mice were 8 week old males or females, as noted. Fifteen tissues were isolated from three mouse strains including C57BL/6, DBA/2J, CD1. All the tissues were stored at -80°C. Most tissues or organs were cut into 2–3 small pieces to purify gDNA. For mouse HSCs, about 105 cells were used to extract gDNA. gDNA samples were extracted using the Maxwell® 16 Tissue DNA Purification Kit in Promega Corporation. The concentration of gDNA samples was measured by Qubit dsDNA HS Assay. For digital droplet PCR, 1 ng template was used per reaction. Digital droplet PCR was used to measure rDNA copy number, performed per the manufacturer’s protocol (Bio-Rad). Briefly, isolated gDNA was digested with the restriction endonuclease Hae III. Reaction mixtures were made with target copy number variable sequence (45S rDNA) and internal control (Gapdh1 for mouse, TBP for human). Droplet generation was performed, followed by endpoint PCR. Each PCR product is detected by a fluorescent probe. Droplets were read by QX200 droplet reader, and quantitation was performed using Quantasoft software. The Pten tamoxifen-inducible SCL-Cre mouse model has been previously described [36]. In brief, mice at 6–8 weeks of age were given 2 mg tamoxifen for 5 days. The 8 pairs of mice used for these experiments were age and sex matched. Both WT and PtenloxP/loxP (Lesche); HSC-Scl-Cre-ErT+ (Göthert) were treated with tamoxifen. HSCs were collected 12 days after the final injection. At this point these cells are considered leukemic stem cells. The timing of development of a clinically defined leukemia in vivo varies in this model, generally occurring within 3–4 months post-induction, but sometimes sooner. The Pten-/- HSC cause leukemia development after transplant. HSCs were sorted (in this case defined as lineage negative, Sca-1+, c-Kit+, and CD34- cells) by flow cytometry into methylcellulose semi-solid medium (M3434 media from Stem Cell Tech.). Single HSCs are sorted into individual wells in a 96-well plate. These single cells will (in about 35–50% of the wells) form a large colony of mainly myeloid and erythroid hematopoietic cells all derived from the single HSC. The individual colonies are harvested by incubating a flooded well in PBS for 20–30 minutes, and pipetting up and down to disassociate the colony. Cells were rinsed once with ice-cold PBS and lysed in ice-cold lysis buffer (buffer A: 50 mM HEPES-KOH (pH 7. 4), 2 mM EDTA, 10 mM pyrophosphate, 10 mM β-glycerophosphate, 40 mM NaCl, 1% Trition X-100 and one tablet of EDTA-free protease inhibitors (Roche) per 25 mL). The soluble fraction of the cell lysate was isolated by centrifugation at 12,000 g for 10 min. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed using NuPAGE Novex 4%–12% Bis-Tris precast gels (Invitrogen). Western blotting was performed per standard protocol using a nitrocellulose (Whatman, Protran) membrane. The following antibodies were used: mTOR (Cell Signaling Technology, #2972), phospho-mTOR (Ser2448) (Cell Signaling Technology, #2971), phospho-S6K1 (Thr389) (Abcam company, ab126818), S6K1 (Cell Signaling Technology, #9202), phospho-RPS6 (Ser235/236) (Cell Signaling Technology, #2211), RPS6 (Santa Cruz Biotechnology, sc-74459), α-tubulin (Sigma Inc. , T6199), phospho-Akt (Ser473) (Cell Signaling Technology, #4060), Akt (Cell Signaling Technology, #9272), PTEN (Cell Signaling Technology, #9188). Secondary antibodies were HRP linked, anti-rabbit IgG (from donkey) and anti-mouse IgG (from sheep), (GE Healthcare, NA934V, NA931V, and NA935V, respectively). The 105−106 Pten+/+ and Pten-/- HSCs were seeded on 8-well chamber slides, with poly-L-lysine pre-coating overnight at 4°C. The HSCs were cultured for 24 hours for cell attachment. Next, the samples were washed in PBS, fixed for 10 min at room temperature 20–22°C with 4% paraformaldehyde, permeabilized for 5 min in PBS containing 0. 5% Triton X-100 and washed in PBS. After blocking for 30 min in PBS containing 1% BSA at room temperature, the preparations were incubated overnight at 4°C with the following antibodies diluted in PBS containing 1% BSA: mouse anti-fibrillarin with 1: 200 dilution, rabbit anti-nucleolin (H-250; Santa Cruz) with 1: 200 dilution. The coverslips were then washed in PBS and incubated for 30 min at room temperature with the secondary antibodies Alexa Fluor 488 goat anti-mouse and Alexa Fluor 555 donkey anti-rabbit (Molecular Probes) diluted in PBS containing 1% BSA and then washed in PBS. The coverslips were mounted on slides and analyzed by fluorescence imaging with a Zeiss Axioplan II confocal microscope. The quantification of nucleolar size was performed in the fibrillarin and nucleolin stained regions using Image J software. Nucleolar size distributions and average sizes were determined using custom ImageJ plugins essentially as in [55] but with minor modifications to account for higher image resolution. Firstly, confocal images were maximum intensity projected. Briefly, a rolling ball background with a radius of 5 pixels was subtracted from each image. Next, images were smoothed with a Gaussian blur of 2 pixels (standard deviation). Finally, images were thresholded at 0. 25 times the maximum processed intensity in the image. Each resulting distinct spot was considered a nucleolar region for area measurements. Methods for rRNA labeling were derived from a previous report [55,56]. The cultured Pten+/+ and Pten-/- HSCs (105−106) were washed in PBS twice, and switched to fresh Dulbecco’s Modified Eagle’s Medium (Sigma) supplemented with 200 μM L-cysteine (BSA, Sigma), 50 μM 2-mercaptoethanol (Sigma), 1 mM L-glutamine (Gibco) and 0. 1% bovine serum albumin (Sigma). HSCs were pulse labeled with 3H-uridine (5 μCi) for the indicated amount of time (0,30,60,120 min) per sample. Total RNA was isolated with TriZol reagent (Invitrogen, U. S. A) and the concentration of each RNA sample was measured by Qubit RNA assay. 1 μg of each sample was counted in a Beckman LS 6500 multipurpose scintillation counter to determine new rRNA production based on 3H-uridine incorporation. Three replicates were used to derive the standard deviation from two pairs of mice (WT and Pten-/-) from the same litter. Significance was calculated using an unpaired t test. Pten+/+ and Pten-/- HSCs (105−106) were plated in 100 μl of methionine/ cysteine -free Dulbecco’s Modified Eagle’s Medium (Sigma) supplemented with 200 μM L-cysteine (Sigma), 50 μM 2-mercaptoethanol (Sigma), 1 mM L-glutamine (Gibco) and 0. 1% BSA. The HSCs were pre-cultured with the fresh medium for one hour to deplete endogenous methionine. HSCs were pre-treated with 10 μM MG-132, a proteasome inhibitor, for 1 hour, and then were labeled with 30 μCi of 35S-methionine for 1 hour. Cells were lysed in RIPA buffer and proteins were precipitated by the addition of hot 10% TCA. After centrifugation, the precipitate was washed twice in acetone. The precipitate was dissolved in 100 μL of 1% SDS and heated at 95°C for 10 min. An aliquot of the SDS extract was counted in Esoscint for 35S radioactivity in a liquid scintillation counter to determine the amount of 35S-methionine incorporated into proteins. To measure growth in the presence of DNA damage, mouse HSCs (3X104) were plated in 100 μl fresh medium containing various DNA damage stresses at the indicated dosages. After culturing for five days, cell viability was assessed based on total cell number and trypan blue staining. Cancer genome data was obtained with permission from dbGaP. The analysis for rDNA copy number is similar to a previously published method [17]. Briefly, the human consensus 45S rDNA sequences was obtained from NCBI (accession: U13369). Raw fastq whole-genome DNA sequence reads were downloaded from dbGaP. Reads were mapped to the 45S locus, and a set of 16022 pre-selected putative single-copy exons (the largest from each gene) using Bowtie2 v2. 1. 0 with default parameters. Only concordant read pairs are kept in the down-stream analysis. The rDNA copy number of 18S, 5. 8S, and 28S was calculated as the mean coverage in the respective regions. To make samples comparable to each other, the rDNA copy number was further normalized to the background genome coverage, which is calculated as the median coverage of the single copy exons. For sequence analysis, the predominant sequence of each individual genome was compared to the human reference sequence for 45S. Each nucleotide position was either a match to the consensus 45S sequence, or if not a match, then the position was called a SNV. SNVs were called using samtools mpileup (v1. 2) after the duplicated reads were removed from the aligned read files. SNVs were further filtered with the quality score (>20, “PASS”). If the SNVs of the cancer and normal matched genome pair were identical, this was termed a shared SNV. If the SNV was not identical, this position was termed a unique SNV. For the shared SNVs in a pair, each position was evaluated for sequence evidence of 1–4 different nucleotides. The allele numbers for the shared SNVs were used to calculate an average allele number for each genome. The average of the number of alleles at the shared SNVs for normal was subtracted from tumor to generate the allele difference for each matched pair, plotted as an individual point in the box plot. GO terms were calculated using the R package GOstats. DNAseq libraries were generated from 1 ng of genomic DNA as assessed by the Qubit 2. 0 Fluorometer (Life Technologies). Libraries were made according to the manufacturer’s directions for the Nextera XT Library Prep Kit (Illumina, Inc.) and purified using the Agencourt AMPure XP system (Beckman Coulter). Resulting libraries were checked for quality and quantity using the LabChip GX (Perkin Elmer) and Qubit. Equal molar libraries were pooled, re-quantified and sequenced as 125 bp paired reads on the Illumina HiSeq 2500 instrument using HiSeq Control Software 2. 2. 58. Following sequencing, Illumina Primary Analysis version RTA 1. 18. 64 and Secondary Analysis version bcl2fastq2 v2. 17 were run to demultiplex reads for all libraries and generate FASTQ files. Human RPE1 cells (hTERT-immortalized retinal pigment epithelial cell line from ATCC), at low passage number and ~70% cell confluence, were transfected by three different PTEN-siRNAs or the control siRNAs (Ambion) using Lipofectamine RNAiMAX Transfection Reagent from Thermo Fisher Scientific company. 24 hours post-transfection, cells were placed in fresh Dulbecco' s Modified Eagle Medium plus 10% Fetal Bovine Serum. At 80 hours post-transfection, cells were harvested. Genomic DNA was extracted using the Maxwell® 16 Blood DNA Purification Kit from Promega Corporation. The DNA concentration was measured using the Qubit dsDNA HS assay, and normalized to 1ng/μL.
The ribosomal DNA encodes the RNAs needed to make ribosomes for protein synthesis and cellular proliferation. However, ribosomal DNA has been excluded from most mammalian genome-wide studies due to challenges associated with its analysis. We find that both the sequence and copy number of the ribosomal DNA can change in human cancer genomes. mTOR is a kinase that senses the nutritional environment and is often over-active in cancer. Given mutational evidence for mTOR activation in the human cancer genomes with loss of ribosomal DNA copies, we analyzed ribosomal DNA in hematopoietic stem cells derived from mice under conditions of mTOR activation. Like the human cancer genomes, the ribosomal DNA copy number contracts in mTOR activated hematopoietic stem cells relative to normal stem cells. Loss is associated with high rates of cellular proliferation, rRNA production, and protein synthesis, but compromised survival in the presence of DNA damage. Contractions are a recurrent feature in cancer genomes with overactive mTOR and may predict sensitivity to DNA damaging chemotherapeutics. Ribosomal DNA may be altered in other disease contexts.
cancer genomics
medicine and health sciences
basic cancer research
invertebrate genomics
oncology
dna damage
animal models
protein synthesis
model organisms
experimental organism systems
mammalian genomics
dna
cellular structures and organelles
chemical synthesis
research and analysis methods
chromosome biology
proteins
mouse models
animal genomics
ribosomes
biosynthetic techniques
biochemistry
rna
ribosomal rna
cell biology
nucleic acids
genetics
biology and life sciences
genomics
non-coding rna
genomic medicine
chromosomes
Ribosomal DNA copy number loss and sequence variation in cancer